Tamoxifen therapy for breast cancer and endometrial cancer risk
Tamoxifen therapy for breast cancer and endometrial cancer risk
复制标题
DOI：
10.1093/jnci/91.19.1654
复制
发表时间：
1999-10-06
期刊：
影响因子：
--
通讯作者：
Ford, L
中科院分区：
文献类型：
--
作者：
Bernstein, L;Deapen, D;Ford, L
背景资料：三苯氧胺能有效治疗乳腺癌，降低高危女性乳腺癌的发病率，并与子宫内膜癌风险增加有关。本研究旨在探讨子宫内膜癌风险因素对三苯氧胺-子宫内膜癌关联的可能修饰作用。研究方法：我们进行了一项子宫内膜癌病例对照研究（324例病例和671例单独匹配的对照受试者），该研究嵌套在美国四个地区1978年至1992年诊断为乳腺癌的患者人群队列中。我们通过访谈和病历回顾获得了乳腺癌治疗和子宫内膜癌危险因素的信息。报告的所有P值均为双侧。结果如下：子宫内膜癌风险与他莫昔芬治疗乳腺癌相关（比值比= 1.52; 95%置信区间[CI] = 1.07-2.17）。风险随着他莫昔芬使用时间的增加而增加（趋势P = 0.0002），暴露于他莫昔芬超过5年的女性患子宫内膜癌的几率比不使用者高4.06倍（95%CI = 1.74-9.47）。既往使用雌激素替代疗法（ERT）增加了与他莫昔芬使用相关的风险（P趋势同质性
Background: Tamoxifen is effective in treating breast cancer, reduces breast cancer incidence among high-risk women, and is associated with increased endometrial cancer risk, This study was designed to examine the possible modifying effects of endometrial cancer risk factors on the tamoxifen-endometrial cancer association. Methods: We conducted a case-control study of endometrial cancer (324 case patients and 671 individually matched control subjects) nested within a population-based cohort of patients with breast cancer diagnosed from 1978 through 1992 within four regions of the United States. We obtained information on breast cancer treatment and endometrial cancer risk factors through interviews and reviews of medical records. All P values reported are two-sided. Results: Endometrial cancer risk was associated with tamoxifen therapy for breast cancer (odds ratio = 1.52; 95% confidence interval [CI] = 1.07-2.17). Risk increased with duration of tamoxifen use (P for trend =.0002), Women with more than 5 years of exposure to tamoxifen had 4.06-fold greater odds of developing endometrial cancer than nonusers (95% CI = 1.74-9.47). Prior use of estrogen replacement therapy (ERT) increased risk associated with tamoxifen use (P for homogeneity of trends